

Appendix 3H

Melbourne, Australia – 25 July 2025: Leading digital health company Adherium Limited (ASX: ADR) (the **Company**) refers to the Appendix 3H lodged with the ASX today in relation to cessation of options.

The Appendix 3H was lodged late due to an administrative oversight. The Company considers that the lodgement was an isolated incident and believes that its current practices are adequate to ensure compliance with the ASX Listing Rules.

- ENDS -

This ASX announcement was approved and authorised for release by the Board.

Investor Enquiries

Adherium Limited
investors@adherium.com

Media Enquiries:

Haley Chartres
HACK Director
haley@hck.digital

About Adherium (ASX: ADR)

Adherium is a provider of integrated digital health solutions and a worldwide leader in connected respiratory medical devices, with more than 180,000 sold globally. Adherium's Hailie® platform solution provides clinicians, healthcare providers and patients access to remotely monitor medication usage parameters and adherence, supporting reimbursement for qualifying patient management. The Hailie® solution includes a suite of integration tools to enable the capture and sharing of health data via mobile and desktop apps, Software Development Kit (SDK) and Application Programming Interface (API) integration tools, and Adherium's own broad range of sensors connected to respiratory medications. Adherium's Hailie® solution is designed to provide visibility to healthcare providers of medication use history to better understand patterns in patient respiratory disease. **Learn more at adherium.com**